CIBUS INC (CBUS)

US17166A1016 - Common Stock

2.69  -0.15 (-5.28%)

After market: 2.69 0 (0%)

Fundamental Rating

2

Taking everything into account, CBUS scores 2 out of 10 in our fundamental rating. CBUS was compared to 565 industry peers in the Biotechnology industry. CBUS has a bad profitability rating. Also its financial health evaluation is rather negative. CBUS is valued quite expensive, but it does show an excellent growth.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

CBUS had negative earnings in the past year.
In the past year CBUS has reported a negative cash flow from operations.
In the past 5 years CBUS always reported negative net income.
In the past 5 years CBUS always reported negative operating cash flow.

1.2 Ratios

The Return On Assets of CBUS (-121.07%) is worse than 80.43% of its industry peers.
Looking at the Return On Equity, with a value of -411.87%, CBUS is doing worse than 78.11% of the companies in the same industry.
Industry RankSector Rank
ROA -121.07%
ROE -411.87%
ROIC N/A
ROA(3y)-67.69%
ROA(5y)-63.77%
ROE(3y)-177.62%
ROE(5y)-143.55%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CBUS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

2

2. Health

2.1 Basic Checks

CBUS does not have a ROIC to compare to the WACC, probably because it is not profitable.
CBUS has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, CBUS has more shares outstanding
The debt/assets ratio for CBUS has been reduced compared to a year ago.

2.2 Solvency

CBUS has an Altman-Z score of -3.18. This is a bad value and indicates that CBUS is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -3.18, CBUS perfoms like the industry average, outperforming 47.51% of the companies in the same industry.
A Debt/Equity ratio of 0.00 indicates that CBUS is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.00, CBUS is in line with its industry, outperforming 47.86% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.18
ROIC/WACCN/A
WACC10.98%

2.3 Liquidity

A Current Ratio of 1.44 indicates that CBUS should not have too much problems paying its short term obligations.
CBUS has a worse Current ratio (1.44) than 81.85% of its industry peers.
CBUS has a Quick Ratio of 1.44. This is a normal value and indicates that CBUS is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.44, CBUS is doing worse than 80.96% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.44
Quick Ratio 1.44

More info and screens

7

3. Growth

3.1 Past

CBUS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -12.99%.
CBUS shows a strong growth in Revenue. In the last year, the Revenue has grown by 446.45%.
The Revenue has been growing by 49.91% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-12.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%103.77%
Revenue 1Y (TTM)446.45%
Revenue growth 3Y-57.61%
Revenue growth 5Y49.91%
Sales Q2Q%250.95%

3.2 Future

CBUS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.79% yearly.
Based on estimates for the next years, CBUS will show a very strong growth in Revenue. The Revenue will grow by 170.47% on average per year.
EPS Next Y60.45%
EPS Next 2Y37.18%
EPS Next 3Y23.92%
EPS Next 5Y14.79%
Revenue Next Year267.86%
Revenue Next 2Y169.86%
Revenue Next 3Y191.67%
Revenue Next 5Y170.47%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CBUS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CBUS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as CBUS's earnings are expected to grow with 23.92% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.18%
EPS Next 3Y23.92%

More info and screens

0

5. Dividend

5.1 Amount

CBUS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CIBUS INC

NASDAQ:CBUS (12/24/2024, 8:00:48 PM)

After market: 2.69 0 (0%)

2.69

-0.15 (-5.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)N/A N/A
Inst Owners31.53%
Inst Owner Change8.09%
Ins Owners16.74%
Ins Owner Change5.9%
Market Cap79.46M
Analysts80
Price Target18.74 (596.65%)
Short Float %10.24%
Short Ratio15.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)34.3%
Min EPS beat(2)-37.98%
Max EPS beat(2)106.57%
EPS beat(4)1
Avg EPS beat(4)-175.82%
Min EPS beat(4)-763.16%
Max EPS beat(4)106.57%
EPS beat(8)2
Avg EPS beat(8)-208.1%
EPS beat(12)6
Avg EPS beat(12)-126.77%
EPS beat(16)7
Avg EPS beat(16)-101.43%
Revenue beat(2)2
Avg Revenue beat(2)127.1%
Min Revenue beat(2)86.72%
Max Revenue beat(2)167.48%
Revenue beat(4)4
Avg Revenue beat(4)117.68%
Min Revenue beat(4)35.27%
Max Revenue beat(4)181.24%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)7.04%
PT rev (3m)-6.96%
EPS NQ rev (1m)23.44%
EPS NQ rev (3m)12.5%
EPS NY rev (1m)-149.62%
EPS NY rev (3m)-150.09%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)18.42%
Revenue NY rev (1m)69.73%
Revenue NY rev (3m)69.73%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 19.13
P/FCF N/A
P/OCF N/A
P/B 0.73
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-14.79
EYN/A
EPS(NY)-2.68
Fwd EYN/A
FCF(TTM)-2.11
FCFYN/A
OCF(TTM)-2.07
OCFYN/A
SpS0.14
BVpS3.66
TBVpS-6.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -121.07%
ROE -411.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-67.69%
ROA(5y)-63.77%
ROE(3y)-177.62%
ROE(5y)-143.55%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 17.13%
Cap/Sales 28.97%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.44
Quick Ratio 1.44
Altman-Z -3.18
F-Score4
WACC10.98%
ROIC/WACCN/A
Cap/Depr(3y)70.93%
Cap/Depr(5y)98.6%
Cap/Sales(3y)396.58%
Cap/Sales(5y)247.59%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%103.77%
EPS Next Y60.45%
EPS Next 2Y37.18%
EPS Next 3Y23.92%
EPS Next 5Y14.79%
Revenue 1Y (TTM)446.45%
Revenue growth 3Y-57.61%
Revenue growth 5Y49.91%
Sales Q2Q%250.95%
Revenue Next Year267.86%
Revenue Next 2Y169.86%
Revenue Next 3Y191.67%
Revenue Next 5Y170.47%
EBIT growth 1Y-49.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-193.71%
EBIT Next 3Y15.49%
EBIT Next 5Y26.7%
FCF growth 1Y-191.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-209.05%
OCF growth 3YN/A
OCF growth 5YN/A